Maraviroc, sold under the brand names Selzentry (US) and Celsentri (EU), is an antiretroviral medication used to treat HIV infection.

[3] The MOTIVATE trials showed no clinically relevant differences in safety between the maraviroc and placebo groups.

The chemokine receptor CCR5 is an essential co-receptor for most HIV strains and necessary for the entry process of the virus into the host cell.

[10] Maraviroc, originally designated UK-427857, was developed by the drug company Pfizer in its UK labs located in Sandwich.

[15] Maraviroc appears to reduce graft-versus-host disease in people treated with allogeneic bone marrow transplantation for leukemia, in a Phase I/II study.